Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y2K2
UPID:
SIK3_HUMAN
Alternative names:
Salt-inducible kinase 3; Serine/threonine-protein kinase QSK
Alternative UPACC:
Q9Y2K2; A1A5A8; H0Y494; J3KPC8; Q59FY2; Q5M9N1; Q6P3R6; Q8IYM8; Q9HA50
Background:
Serine/threonine-protein kinase SIK3, also known as Salt-inducible kinase 3 and Serine/threonine-protein kinase QSK, plays a pivotal role in mTOR signaling, crucial for chondrocyte differentiation and skeletogenesis. It acts by promoting the degradation of DEPTOR, an inhibitor of mTOR, and negatively regulates the cAMP signaling pathway, impacting cellular processes.
Therapeutic significance:
SIK3's involvement in Spondyloepimetaphyseal dysplasia, Krakow type, a skeletal disorder marked by severe developmental challenges and immunodeficiency, underscores its therapeutic potential. Understanding the role of Serine/threonine-protein kinase SIK3 could open doors to potential therapeutic strategies for treating skeletal dysplasias and related immunodeficiencies.